Features

Features

ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain

Upon its rise to notoriety spearheaded by drugs like Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the radiopharmaceutical field is…

Annabel Kartal Allen

Features

How biotech executives are confronting funding and regulatory shifts

Features

Can AI predict the (regulatory) future?

Interviews

Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact

Features

Dangerous waters: Geopolitics, supply chains and access to medicines

Features

Novo Nordisk puts AI at the centre of its clinical strategy

Features

Shift in biosimilar commercial landscape essential for sector sustainability, expert says

Features

ASCO26 Podcast: an analyst rundown of the best readouts and key trends

Features

Psychedelic-assisted therapies get a boost, but systems struggle to play catch-up

Features

Validation to velocity: Japan’s pharma model comes under execution pressure

Catherine Longworth

Features

Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends

Features

AI-guided labs are approaching full autonomy

Frankie Fattorini

Features

Podcast: Autonomous labs redefine the role of biopharma researchers

Frankie Fattorini

Features

Non-viral gene therapies emerge as key players amid viral safety bottlenecks

Annabel Kartal Allen

Features

EU’s Joint Clinical Assessment system still finding its footing

Features

The slow march of clinical biomarkers to become surrogate endpoints

Frankie Fattorini

Features

Magazine: Digital twins become the new battleground for CDMOs

Features

The innovators working to make in vivo cell therapy a reality

Frankie Fattorini

Features

Non-invasive diagnostics in endometriosis: at the cusp of a turning point

Features

Navigating commercial gaps to supercharge the UK life sciences sector

Annabel Kartal Allen

Features

Podcast: European biotech rallies against US and China powerhouses

Features

Researchers become scientific tastemakers by handing more R&D to autonomous labs

Frankie Fattorini

Features

Widespread US shift from prescription to OTC lies in pharma’s hands

Annabel Kartal Allen

Features

Building for decades: Dubai’s long game in life sciences

Catherine Longworth

Features

Women first: the Gulf’s new healthcare blueprint

Catherine Longworth

Features

Targeted therapies to join chemo as oncology treatment backbone

Annabel Kartal Allen

Features

Europe’s pharma trade with the US remains critical despite tariff turmoil

Frankie Fattorini

Features

How America’s former steel heartland secured a $3.5bn Eli Lilly facility

Features

Podcast: Rare Disease Day: FDA guidance allowing advancement

Abigail Beaney , Robert Barrie and Frankie Fattorini

Features

Rare disease developers applaud clarity in FDA guidance

Features

Nonprofit models support strategic boldness to develop gene therapies for rare diseases

Features

Podcast: Which pharma and medtech companies came out on top in 2025 revenues?

Features

RNA-targeting small molecules: a new frontier of drug discovery

Features

Theranostics earmarked as “the future” of radiopharmaceuticals

Annabel Kartal Allen

Features

Pharma eyes AI deals to stem lost revenues from patent expirations

Frankie Fattorini

Features

FDA’s commissioner vouchers prompt questions about award process

Features

Magazine: Smart and connected packaging

Features

Why pharma manufacturers are still investing in Europe

Frankie Fattorini

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close